Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology
| Autor: | Reema H. Syed, Terry L. Moore, Brooke E Gilliam |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty genetic structures Arthritis Peptides Cyclic Rheumatology Disease severity Rheumatoid Factor immune system diseases Internal medicine medicine Humans Rheumatoid factor Pediatric rheumatology Child skin and connective tissue diseases Autoantibodies biology business.industry Childhood disease medicine.disease Arthritis Juvenile Immunoglobulin Isotypes Rheumatoid arthritis Immunology biology.protein Antibody business Biomarkers |
| Zdroj: | Current Rheumatology Reports. 10:156-163 |
| ISSN: | 1534-6307 1523-3774 |
| Popis: | Juvenile idiopathic arthritis (JIA) is a heterogenous childhood disease without reliable biomarkers for monitoring disease progression. Immunoglobulin (Ig) M rheumatoid factor (RF) is used to define a subset of JIA patients, but its significance in JIA is dependent on the method of measurement. In addition to IgM RF, IgA RF has been implicated in determining disease severity in JIA, including functional disability and joint damage. Anticyclic citrullinated peptide (anti-CCP) antibodies have been a valuable diagnostic tool in rheumatoid arthritis, with varied results in their significance in JIA patients. Recent studies have demonstrated the possible usefulness of isotypes of anti-CCP antibodies in monitoring JIA patients to determine disease outcome. Overall, RF isotypes and anti-CCP isotypic antibodies have demonstrated increasing importance in the evaluation of JIA patients to determine which patients may have more aggressive or severe disease and to aid in possible treatment plans to prevent joint damage and disability. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink